Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Idiopathic Pulmonary Fibrosis | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

Background Since 2009, IPF patients across Europe are recruited into the eurIPFreg,
providing epidemiological data and biomaterials for translational research. Methods The …

Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological
processes, indicating the potential for common approaches to treatment. Nintedanib …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disorder driven by
unrelenting extracellular matrix deposition. Fibroblasts are recognized as the central …

Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …

Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and
high mortality. Numerous studies have documented acute exacerbation in idiopathic …